- Advanced search
- Immuno Portal
- Malaria Portal
Molecular properties generated using the CDK
|No information available.|
|Summary of Clinical Use|
|In some jurisdictions ambroxol is used as an orally delivered expectorant drug . It is not yet authorised for use by the FDA or the EMA (but is approved by individual European agencies). Clinical evaluation as an expectorant are ongoing for future US approval.
Ambroxol (as the hydrochloride) is being repurposed as a novel candidate for neurodegenerative diseases including Parkinson's disease (in particular in patients with defective β-glucocerebrosidase GBA1 genes [10,13]) [7,14] and amyotrophic lateral sclerosis (ALS; motor neurone disease; MND) [2,6]. Click here to link to ClinicalTrials.gov's full list of ambroxol studies. In July 2018, the EMA granted orphan designation for ambroxol hydrochloride to be used as a treatment for ALS/MND.
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT02914366||Ambroxol as a Treatment for Parkinson's Disease Dementia||Phase 2 Interventional||Lawson Health Research Institute|
|NCT03843541||A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions||Phase 3 Interventional||Zambon SpA|
|NCT02941822||Ambroxol in Disease Modification in Parkinson Disease||Phase 2 Interventional||University College, London|